Forest Laboratories, Inc.
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
Published in Lab Business Week, March 16th, 2008
Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of Forest Laboratories, Inc. (NYSE:FRX), announced that it and Mylan Inc. (NYSE:MYL) have amended their January 2006 agreement to commercialize, develop and distribute the novel beta blocker Bystolic(TM) (nebivolol), which is currently approved in the United States for the treatment of hypertension. The companies have agreed that Forest will assume Mylan's commercial rights for Bystolic in the United States and Canada including, but not limited to, the elimination of Mylan's option to co-promote the product. Forest will be responsible for all future Bystolic development expenses as well as all sales and marketing expenses for...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
Source: Lab Business Week (2008-03-16)
More Articles from Lab Business Week
- Analgesics
Findings from Abbott Laboratories advance knowledge in analgesics - Biologics
Mylan Announces Appointment of Patrick Vink as Senior Vice President in New Position of Global Head of Biologics - Botanical Laboratories, Inc.
WELLESSE(TM) Announces the 'Keep Your Body in Motion' Sweepstakes - Carrington Laboratories, Inc.
Carrington and Universal Harvest Sign Supply Agreement - GSS Lab.
Scientific Discovery: Massage felt all over the body via the nervous system - HIV/AIDS
GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials - More from this issue of Lab Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
